New hope for rare nerve disorder: drug trial targets underlying cause
NCT ID NCT07392229
First seen Feb 06, 2026 · Last updated May 07, 2026 · Updated 12 times
Summary
This study tests a drug called zanubrutinib in 50 adults with a rare nerve disease (anti-MAG neuropathy) that causes numbness, weakness, and balance problems. The drug aims to stop the immune system from attacking nerves, potentially improving movement and sensation. Participants take the drug for 12 months, and doctors check if their symptoms get better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UOC Ematologia, Azienda Ospedale Università Padova
RECRUITINGPadova, PD, 35128, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.